Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-01-18
2005-01-18
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S016700, C514S017400, C514S018700, C514S034000, C530S322000, C530S328000, C530S329000, C530S330000, C536S006400
Reexamination Certificate
active
06844318
ABSTRACT:
This invention is directed to antineoplastic agents conjugated to enzyme-cleavable peptides comprising the amino acid recognition sequence of a membrane-bound and/or cell-secreted peptidase, and to the use of such conjugated compounds as chemotherapeutic agents in the targeted treatment of cancers.
REFERENCES:
patent: 4703107 (1987-10-01), Monsigny et al.
patent: 5853713 (1998-12-01), Cooper et al.
patent: 5962216 (1999-10-01), Trouet et al.
patent: 6303569 (2001-10-01), Greenwald et al.
patent: 6342480 (2002-01-01), Trouet et al.
patent: 20020147138 (2002-10-01), Firestone et al.
patent: 126685 (1984-11-01), None
patent: 359347 (1990-03-01), None
patent: 2131813 (1984-06-01), None
patent: WO 9600503 (1996-01-01), None
patent: WO 9605863 (1996-02-01), None
patent: WO 9712624 (1997-04-01), None
patent: WO 9714416 (1997-04-01), None
patent: WO 9748725 (1997-12-01), None
patent: WO 9810651 (1998-03-01), None
patent: WO 9810795 (1998-03-01), None
patent: WO 9816240 (1998-04-01), None
patent: WO 9818493 (1998-05-01), None
patent: WO 9846250 (1998-10-01), None
patent: WO 9902175 (1999-01-01), None
patent: WO 0033888 (2000-06-01), None
patent: WO 0059930 (2000-10-01), None
patent: WO 0064486 (2000-11-01), None
patent: WO 0071571 (2000-11-01), None
Bassiouny et al. Flow Regulation of 72-kD Collagenase IV (MMP-2) After Experimental Aterial Injury. Circulation. vol. 98, pp. 157-163 (1998).*
Timar et al, “The antiproliferative action of a melphalan hexapeptide with collagenase-cleavable site” Cancer Chemotherapy Pharmacology, vol. 41, No. 4, 1998, 292-298.
Masquelier et al, “Amino Acid and Dipeptide Derivatives of Daunorubicin. 1. Synthesis, Physicochemical Properties, and Lysosomal Digestion”, Journal of Medicinal Chemistry, American Chemical Society, vol. 23, No. 11, 1980, 1166-1170.
Denmeade et al, “Enzymatic Activation of a Doxorubicin-Peptide Prodrug by Prostate-Specific Antigen”, Cancer Research, American Assoc. for Cancer Research, vol. 58, Jun. 15, 1998, 2537-2540.
Safavy et al, “Paclitaxel Derivatives for Targeted Therapy of Caner: Toward the Development of Smart Taxanes” Journal of Medicinal Chemistry, Am. Chem. Soc., vol. 42, 1999, 4919-4924.
McGeehan et al, “Characterization of the Peptide Substrate Specificities of Interstitial Collagenase and 92-KDA Gelatinase Implications of Substrate Optimization” Journal of Biological Chem., vol. 269, No. 52, Dec. 30, 1994, 32814-32820.
Aimes et al, Matrix Metalloproteinase-2 Is an Interstital Collagenase, Journal of Biological Chemistry, vol. 270, No. 11, Mar. 17, 5872-5876, 1995.
Kurschat et al, Tissue Inhibitor or Matrix Metalloproteinase-2 Regulates Matrix Metalloproteinase-2 Activation by Modulation of Membrane-type 1 Matrix Metalloproteinase Activity in High and Low Invasive Melanoma Cell Lines, Journal of Biological Chemistry, vol. 274, No. 30, 21056-21062, 1999.
Garbisa et al, Correlation of Serum Metalloproteinase Levels with Lung Cancer Metastasis and Response to Therapy, Cancer Research, 52, 4548-4549, 1992.
Boven et al, Doxorubicin Compared with Related Compounds in a Nude Mouse Model for Human Ovarian Cancer, Eur. J. Cancer, vol. 26, No. 9, 983-986, 1990.
Knauper et al, Biochemical Characterization of Human Collagenase-3, Biological Chemistry, vol. 271, No. 3, 1544-1550, 1996.
Brooks et al, Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interation with Integrin ανβ3, Cell, vol. 85, 683-693, 1996.
Moses et al, Increased Incidence of Matrix Metalloproteinases in Urine of Cancer Patients, Cancer Research, 58, 1395-1399, 1998.
Canal et al, Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities, Clin. Pharmacol. Ther., vol. 51, No. 3, 249-259, 1992.
Boven et al, The anti-tumour effects of the prodrugs N-I-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts, Br. J. Cancer, 66, 1044-1047, 1992.
McDonnell et al, Role of matrix metalloproteinases in invasion and metastasis: biology, diagnosis and inhibitors, Cytotechnology, 12, 367-384, 1993.
Brummer et al, Matrix-metalloproteinases 1, 2 and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study, Virchows Arch, 435, 566-573, 1999.
MacDougall et al, Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis, Cancer and Metastasis Reviews, 14, 351-362, 1995.
De Jong et al, Plasma Pharmacokinetics and Pharmacodynamics of a New Prodrug N-I-Leucyldoxorubicin and Its Metabolities in a Phase I Clinical Trail, Journal of Clinical Oncology, vol. 10, No. 12, 1897-1906, 1992.
De Groot et al, Synthesis and Biological Evaluation of Novel Prodrugs of Anthracyclines for Selective Activation by the Tumor-Associated Protease Plasmin, J. Med. Chem., 42, 5277-5283, 1999.
Nagase et al, Human Matrix Metalloproteinase Specificity Studies Using Collagen Sequence-Based Synthetic Peptides, Biopolymers, vol. 40, 399-416, 1996.
Whittaker et al, Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors, Chem. Rev. 99, 2735-2776, 1999.
Albright Charles F.
Combs Andrew P.
Copeland Robert A.
DiMeo Susan V.
Dowling Randine L.
Bristol - Myers Squibb Pharma Company
Korsen Elliot
Russel Jeffrey Edwin
LandOfFree
Peptidase-cleavable, targeted antineoplastic drugs and their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptidase-cleavable, targeted antineoplastic drugs and their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptidase-cleavable, targeted antineoplastic drugs and their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3429752